| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1027309366 |
| P356 | DOI | 10.1038/NRC.2016.83 |
| P698 | PubMed publication ID | 27658528 |
| P50 | author | Kristian Helin | Q24704761 |
| Itys Comet | Q55458625 | ||
| Benjamin Leblanc | Q55458627 | ||
| Eva M Riising | Q55459503 | ||
| P2860 | cites work | ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression | Q24296658 |
| An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB | Q24299235 | ||
| Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity | Q24305075 | ||
| Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas | Q24339074 | ||
| The genetic basis of early T-cell precursor acute lymphoblastic leukaemia | Q24601515 | ||
| Loss of miR-200 Inhibition of Suz12 Leads to Polycomb-Mediated Repression Required for the Formation and Maintenance of Cancer Stem Cells | Q24610880 | ||
| Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing | Q24612248 | ||
| Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas | Q24629777 | ||
| Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma | Q24630610 | ||
| EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells | Q24672969 | ||
| The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells | Q24680814 | ||
| Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker | Q84025680 | ||
| A687V EZH2 is a gain-of-function mutation found in lymphoma patients | Q84689750 | ||
| Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation | Q88128182 | ||
| The molecular basis for metameric pattern in the Drosophila embryo | Q114755591 | ||
| EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis | Q41543905 | ||
| Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer | Q41942526 | ||
| A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia | Q42053261 | ||
| Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer | Q42491095 | ||
| H3K36me3 key to Polycomb-mediated gene silencing in lineage specification | Q42566361 | ||
| PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies | Q42704491 | ||
| Dense chromatin activates Polycomb repressive complex 2 to regulate H3 lysine 27 methylation | Q43571544 | ||
| The Polycomb-group gene eed regulates thymocyte differentiation and suppresses the development of carcinogen-induced T-cell lymphomas | Q43861822 | ||
| EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms | Q44617220 | ||
| Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. | Q46045890 | ||
| Ten different Polycomb group genes are required for spatial control of the abdA and AbdB homeotic products | Q47070468 | ||
| Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma. | Q47687051 | ||
| Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma | Q48329991 | ||
| Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. | Q50594569 | ||
| Gene silencing triggers polycomb repressive complex 2 recruitment to CpG islands genome wide. | Q50650644 | ||
| Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. | Q50803016 | ||
| Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. | Q51848454 | ||
| Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. | Q51956004 | ||
| Polycomb Group proteins: an evolutionary perspective. | Q51971914 | ||
| Recruitment of components of Polycomb Group chromatin complexes in Drosophila. | Q52584270 | ||
| Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer. | Q52889035 | ||
| A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis | Q57261238 | ||
| Revolution in the Polycomb hierarchy | Q60483612 | ||
| A double take on bivalent promoters | Q26823816 | ||
| Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids | Q27314878 | ||
| Structure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic Mutations | Q27681082 | ||
| Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin | Q27851546 | ||
| Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes | Q27851571 | ||
| Control of developmental regulators by Polycomb in human embryonic stem cells | Q28235841 | ||
| SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 | Q28269618 | ||
| Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma | Q28304953 | ||
| The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer | Q28480584 | ||
| The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation | Q28508260 | ||
| EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas | Q28741454 | ||
| Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) | Q29147438 | ||
| Occupying Chromatin: Polycomb Mechanisms for Getting to Genomic Targets, Stopping Transcriptional Traffic, and Staying Put | Q29301233 | ||
| Polycomb complexes repress developmental regulators in murine embryonic stem cells | Q29547274 | ||
| The Polycomb complex PRC2 and its mark in life | Q29547358 | ||
| A gene complex controlling segmentation in Drosophila | Q29547506 | ||
| Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders | Q29614510 | ||
| Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions | Q29614512 | ||
| The polycomb group protein EZH2 is involved in progression of prostate cancer | Q29614514 | ||
| EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations | Q29615392 | ||
| Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma | Q29616862 | ||
| Epigenetic stem cell signature in cancer | Q29622897 | ||
| Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer | Q29622925 | ||
| Chromosomal distribution of PcG proteins during Drosophila development | Q33239849 | ||
| A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing | Q33268624 | ||
| Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation | Q33691942 | ||
| Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma | Q33710169 | ||
| GC-rich sequence elements recruit PRC2 in mammalian ES cells | Q33775517 | ||
| The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. | Q33915185 | ||
| Altered distributions of Ultrabithorax transcripts in extra sex combs mutant embryos of Drosophila | Q33932029 | ||
| Genetic analysis of the enhancer of zeste locus and its role in gene regulation in Drosophila melanogaster | Q33956903 | ||
| Chromatin proteins and modifications as drug targets | Q34038652 | ||
| Regulation of tumor angiogenesis by EZH2. | Q34073170 | ||
| Short sequences can efficiently recruit histone H3 lysine 27 trimethylation in the absence of enhancer activity and DNA methylation | Q34082870 | ||
| Analysis of the coding genome of diffuse large B-cell lymphoma | Q34205133 | ||
| Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation | Q34213023 | ||
| The controversial role of the Polycomb group proteins in transcription and cancer: how much do we not understand Polycomb proteins? | Q38260253 | ||
| Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. | Q38329285 | ||
| Context-dependent actions of Polycomb repressors in cancer | Q38518851 | ||
| Targeting Polycomb systems to regulate gene expression: modifications to a complex story | Q38595464 | ||
| An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. | Q38773915 | ||
| A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation | Q38953489 | ||
| PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. | Q38954754 | ||
| Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma | Q39021479 | ||
| Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming | Q39140073 | ||
| EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity | Q39175582 | ||
| The molecular basis for metameric pattern in the Drosophila embryo | Q39467660 | ||
| The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states | Q39487525 | ||
| Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation | Q39614645 | ||
| Genome-wide analysis of Polycomb targets in Drosophila melanogaster | Q40274308 | ||
| Genome-wide profiling of PRC1 and PRC2 Polycomb chromatin binding in Drosophila melanogaster | Q40289607 | ||
| EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer | Q34268216 | ||
| A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells | Q34302726 | ||
| Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation | Q34317380 | ||
| An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1 | Q34341058 | ||
| Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas | Q34397318 | ||
| EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors | Q34460151 | ||
| EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling | Q34584872 | ||
| Suz12 binds to silenced regions of the genome in a cell-type-specific manner | Q34703113 | ||
| Chromatin sampling--an emerging perspective on targeting polycomb repressor proteins | Q34976950 | ||
| Ras-induced changes in H3K27me3 occur after those in transcriptional activity | Q34979388 | ||
| Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation | Q35208075 | ||
| Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia | Q35742745 | ||
| Polycomb repressive complex 2 is required for MLL-AF9 leukemia | Q35882496 | ||
| A DNA hypermethylation module for the stem/progenitor cell signature of cancer. | Q35914847 | ||
| Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis | Q36424889 | ||
| SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus | Q36710858 | ||
| Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms | Q36810306 | ||
| Epigenetics: core misconcept | Q36820068 | ||
| Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. | Q36835530 | ||
| The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression | Q36850449 | ||
| EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation | Q36926825 | ||
| Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition | Q37079770 | ||
| Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer | Q37198891 | ||
| Repression of E-cadherin by the polycomb group protein EZH2 in cancer | Q37212534 | ||
| EZH2 mutations are frequent and represent an early event in follicular lymphoma | Q37272035 | ||
| BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. | Q37360243 | ||
| Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma | Q37533656 | ||
| EZH2 expands breast stem cells through activation of NOTCH1 signaling | Q37612687 | ||
| Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins | Q37791830 | ||
| Silencing chromatin: comparing modes and mechanisms | Q37827337 | ||
| The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics | Q38059391 | ||
| A new world of Polycombs: unexpected partnerships and emerging functions | Q38161767 | ||
| Chromatin repressive complexes in stem cells, development, and cancer | Q38218179 | ||
| Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma | Q38259785 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 803-810 | |
| P577 | publication date | 2016-09-23 | |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | Maintaining cell identity: PRC2-mediated regulation of transcription and cancer | |
| P478 | volume | 16 |
| Q91559728 | A lncRNA coordinates with Ezh2 to inhibit HIF-1α transcription and suppress cancer cell adaption to hypoxia |
| Q47106602 | A missense variant in EZH2 is associated with colorectal cancer risk in a Chinese population |
| Q91710710 | AMPK lifts the PRC2-implemented gene repression |
| Q57167864 | ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response? |
| Q58724028 | Accurate Recycling of Parental Histones Reproduces the Histone Modification Landscape during DNA Replication |
| Q52313298 | Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin. |
| Q46629789 | Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer. |
| Q91528840 | An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis |
| Q90352330 | An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer |
| Q90612159 | Application of immunohistochemistry in diagnosis and management of malignant mesothelioma |
| Q91711215 | C9orf72 and triplet repeat disorder RNAs: G-quadruplex formation, binding to PRC2 and implications for disease mechanisms |
| Q55177661 | Cancer epigenetics: Moving forward. |
| Q50458426 | Chromatin biology: Breaking into the PRC2 cage. |
| Q90854205 | Chromatin regulatory mechanisms and therapeutic opportunities in cancer |
| Q95592520 | Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAFV600E by synergistically decreasing global trimethylation of H3K27 |
| Q94530153 | Controlling gene activation by enhancers through a drug-inducible topological insulator |
| Q92340106 | Correlations between chromobox homolog 8 and key factors of epithelial-mesenchymal transition in hepatocellular carcinoma |
| Q58616046 | De novo recruitment of Polycomb-group proteins in embryos |
| Q64264591 | Deregulated expression of NKL homeobox genes in T-cell lymphomas |
| Q96950713 | Deterministic culturing of single cells in 3D |
| Q94591294 | Disruption of ATRX-RNA interactions uncovers roles in ATRX localization and PRC2 function |
| Q92420387 | EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells |
| Q62766307 | EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains |
| Q92881078 | EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia |
| Q91216637 | Engaging chromatin: PRC2 structure meets function |
| Q89093847 | Enhancer of zeste homolog 2 (Ezh2) controls bone formation and cell cycle progression during osteogenesis in mice |
| Q64245254 | Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer |
| Q38696030 | Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer |
| Q55037574 | Epigenetic and Transcriptional Pre-patterning—An Emerging Theme in Cortical Neurogenesis. |
| Q98290375 | Epigenetic mechanisms and the hallmarks of cancer: an intimate affair |
| Q56889801 | Epigenetic mechanisms of tumor resistance to immunotherapy |
| Q39448979 | Epigenetic plasticity and the hallmarks of cancer. |
| Q96304529 | Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses |
| Q51770872 | Epigenetics and MicroRNAs in Cancer. |
| Q38648105 | Epigenome profiling and editing of neocortical progenitor cells during development. |
| Q40093402 | Epstein-Barr virus: a master epigenetic manipulator |
| Q60300338 | Ezh2 programs T differentiation by integrating phosphorylation-dependent activation of Bcl6 and polycomb-dependent repression of p19Arf |
| Q90243494 | G-tract RNA removes Polycomb repressive complex 2 from genes |
| Q57022597 | H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features |
| Q92297581 | Histone H2AK119 Mono-Ubiquitination Is Essential for Polycomb-Mediated Transcriptional Repression |
| Q92986387 | Histone H3 tail binds a unique sensing pocket in EZH2 to activate the PRC2 methyltransferase |
| Q88568406 | Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer |
| Q50446893 | Histone demethylases Kdm6ba and Kdm6bb redundantly promote cardiomyocyte proliferation during zebrafish heart ventricle maturation. |
| Q93153929 | Hybrid analysis of gene dynamics predicts context-specific expression and offers regulatory insights |
| Q33633473 | Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma |
| Q38156730 | Inhibitors of the Histone Methyltransferases EZH2/1 Induce a Potent Antiviral State and Suppress Infection by Diverse Viral Pathogens |
| Q42019561 | Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer. |
| Q64101467 | Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma |
| Q64939994 | Lamin B1 loss promotes lung cancer development and metastasis by epigenetic derepression of RET. |
| Q56525266 | Live-cell imaging reveals the dynamics of PRC2 and recruitment to chromatin by SUZ12-associated subunits |
| Q55317685 | Live-cell single-molecule dynamics of PcG proteins imposed by the DIPG H3.3K27M mutation. |
| Q92542982 | Long Non-coding RNA LINC-PINT Suppresses Cell Proliferation and Migration of Melanoma via Recruiting EZH2 |
| Q64235582 | Lysine 27 of replication-independent histone H3.3 is required for Polycomb target gene silencing but not for gene activation |
| Q91825023 | MEG8 long noncoding RNA contributes to epigenetic progression of the epithelial-mesenchymal transition of lung and pancreatic cancer cells |
| Q58374489 | MTF2 recruits Polycomb Repressive Complex 2 by helical-shape-selective DNA binding |
| Q64387686 | MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells |
| Q41286875 | MUC1-C activates EZH2 expression and function in human cancer cells. |
| Q48146766 | MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells. |
| Q50420115 | Mbf1 ensures Polycomb silencing by protecting E(z) mRNA from degradation by Pacman. |
| Q91816889 | Methyltransferase Inhibitors: Competing with, or Exploiting the Bound Cofactor |
| Q58554385 | Multiple polycomb epigenetic regulatory proteins are active in normal and regenerating adult olfactory epithelium |
| Q48136042 | Multiple roles of Ring 1 and YY1 binding protein in physiology and disease |
| Q46324475 | Notch Signaling Controls Transdifferentiation of Pulmonary Neuroendocrine Cells in Response to Lung Injury. |
| Q92287712 | ONECUT2 overexpression promotes RAS-driven lung adenocarcinoma progression |
| Q49912296 | Oncohistones: drivers of pediatric cancers. |
| Q92610412 | PHF1 fusions cause distinct gene expression and chromatin accessibility profiles in ossifying fibromyxoid tumors and mesenchymal cells |
| Q92429871 | PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation |
| Q49972333 | PRC2 Is Dispensable in Vivo for β-Catenin-Mediated Repression of Chondrogenesis in the Mouse Embryonic Cranial Mesenchyme. |
| Q90076776 | PRC2 activates interferon-stimulated genes indirectly by repressing miRNAs in glioblastoma |
| Q47684416 | PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors |
| Q90696382 | PTE, a novel module to target Polycomb Repressive Complex 1 to the human cyclin D2 (CCND2) oncogene |
| Q89823493 | PVT1 Long Non-coding RNA in Gastrointestinal Cancer |
| Q41573279 | Polycomb Repressor Complex 2 in Genomic Instability and Cancer |
| Q57188777 | Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms |
| Q47859713 | Polycomb-like proteins link the PRC2 complex to CpG islands. |
| Q52342542 | Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity. |
| Q52568730 | Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells. |
| Q92129386 | RNA exploits an exposed regulatory site to inhibit the enzymatic activity of PRC2 |
| Q93207151 | Recent Structural Insights into Polycomb Repressive Complex 2 Regulation and Substrate Binding |
| Q93005015 | Redistribution of EZH2 promotes malignant phenotypes by rewiring developmental programmes |
| Q89575670 | Replicational Dilution of H3K27me3 in Mammalian Cells and the Role of Poised Promoters |
| Q41686751 | SWI/SNF complex in cancer |
| Q33572252 | Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment. |
| Q47948466 | Structure, mechanism, and regulation of polycomb repressive complex 2. |
| Q93160669 | Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia |
| Q99419066 | Targeted inhibition of KDM6 histone demethylases eradicates tumor-initiating cells via enhancer reprogramming in colorectal cancer |
| Q55496828 | Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. |
| Q59349013 | Targeting RNA in mammalian systems with small molecules |
| Q52323206 | Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. |
| Q90288575 | Tazemetostat: First Approval |
| Q48186262 | Tetracycline-controllable artificial microRNA-HOTAIR + EZH2 suppressed the progression of bladder cancer cells. |
| Q64108423 | The Down-Regulation of SUZ12 Accelerates the Migration and Invasion of Liver Cancer Cells via Activating ERK1/2 Pathway |
| Q91045747 | The functional mechanisms of mutations in myelodysplastic syndrome |
| Q59126071 | The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p |
| Q98196633 | The role of histone methylation in the development of digestive cancers: a potential direction for cancer management |
| Q91595196 | The roles of DNA, RNA and histone methylation in ageing and cancer |
| Q89542264 | Three classes of response elements for human PRC2 and MLL1/2-Trithorax complexes |
| Q93083199 | Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma |
| Q58782844 | Unbiased shRNA screening, using a combination of FACS and high-throughput sequencing, enables identification of novel modifiers of Polycomb silencing |
| Q98463513 | Ybx1 fine-tunes PRC2 activities to control embryonic brain development |
| Q91641243 | hPCL3S promotes proliferation and migration of androgen-independent prostate cancer cells |
| Q60913452 | lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer |
Search more.